Form 4: MAIA Biotechnology Director, Cristian Luput, Reports Stock Option Grant
SEC Form 4 Filing
Director Cristian Luput reports acquisition of stock options in MAIA Biotechnology, Inc.
Summary
- On March 31, 2024, Cristian Luput, a director of MAIA Biotechnology, Inc., acquired 9,193 stock options.
- The options were granted pursuant to the company's 2021 Equity Incentive Plan.
- The options vest immediately and are exercisable from the grant date.
- The exercise price of the options is $2.20.
- The options expire on March 31, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, indicating a neutral sentiment.
Positives
- The grant of stock options aligns the director's interests with those of the shareholders.
- The immediate vesting of the options may incentivize the director to contribute to the company's success.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Stakeholder Impact
- The stock option grant may incentivize the director to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 03/31/2024 | Date of earliest transaction (stock option grant) |
| 03/31/2024 | Stock options granted, vest 100%, and are exercisable |
| 03/31/2034 | Expiration date of the stock options |
| 04/02/2024 | Date of Form 4 signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.